Clinical Trials Logo
  1. Home
  2. Cognitive Dysfunction
  3. NCT04369157
  4. Details
NCT04369157 Clinical Trial

Zinc and Post-Operative Cognitive Dysfunction

Cognitive Dysfunction Clinical Trial

Official title:
The Role of Zinc and Inflammation in Susceptibility to Post-operative Cognitive Dysfunction

Clinical Trial Details — Status: Withdrawn

Administrative data
NCT number NCT04369157
Other study ID # RDG-006
Secondary ID
Status Withdrawn
Phase
First received
Last updated
Start date January 1, 2021
Est. completion date June 23, 2021

Study information
Verified date June 2021
Source University of Reading
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

A decline in cognitive abilities following surgery (POCD: Post-Operative Cognitive Dysfunction) affects up to 47% of patients undergoing a surgical procedure. Risk factors include age, previous depression, alcohol and drug use, smoking, cognitive impairment as well as pre-operative biochemical and haematological abnormalities. Inflammation has been proposed as a potential cause, however, there is little empirical and clinical evidence in this area to determine aetiology or reduce risk of incidence. Zinc is an important metal for brain function, with deficiency associated with poorer cognitive outcomes. In relation to POCD, biomarker studies have revealed that levels of a zinc-alpha-2-glycoprotein (AZGP1) were lower in patients with POCD. AZGP1 is a multifunctional glycoprotein implicated in cell adhesion, immune response, transmembrane transport and cellular proliferation. Microglia, the immune cells of the brain, are highly sensitive to changes in zinc which have been proposed to contribute to neurodegenerative disease as well as POCD. However, whilst animal studies looking at the effects of zinc on cognition have been promising, robust human trials are lacking. This research aims to establish the role of zinc in POCD by determining associations between zinc status, inflammation, cognitive function, and biomarkers of POCD risk and incidence. This will be achieved by gathering clinical and cognitive data from a sample of older adults undergoing surgery. Blood samples will be taken pre and post-operatively to establish zinc status and plasma concentrations of biomarkers of POCD risk and incidence. Pre and post-operative cognitive assessments will also be conducted to measure memory and executive function. Incidence of POCD will be determined via neurological assessment according to diagnostic criteria. Should associations between zinc status, POCD biomarkers, inflammation, cognitive performance and POCD incidence be established, not only would it lead to future work to investigate potential mechanisms of action as well as intervention studies looking to support zinc status, optimising early identification of individuals who may be at higher risk of developing POCD should lead to better patient outcomes.

Description:

Healthy older adults under-going elective surgery (knee replacement, hip replacement or colorectal surgery) will be recruited via the Royal Berkshire Hospital. Participants will be aged 60 years and above, will have the capacity to give fully informed consent and will be undergoing elective orthopaedic or colorectal surgery. Participation will involve testing on 3 occasions: 48hours-3 weeks prior to surgery (in the participant's home), 1-3 days post-surgery (in the Royal Berkshire Hospital) and approximately one month post-surgery (in the participant's home). On each occasion, the Montreal Cognitive Assessment (MoCA) and Confusion Assessment Method (CAM) will be administered along with various cognitive tests measuring executive function (Trials A & B, Stroop, Letter memory task, verbal fluency) and memory (the episodic memory tests of free recall and recognition from the CERAD: Consortium to Establish a Registry for Alzheimer's Disease neuropsychological test battery), as well as completion of questionnaires to determine mood (the Hospital Anxiety and Depression Scale [HADS] and the Positive and Negative Affect Scale [PANAS]) and sleep quality (the Pittsburgh Sleep Quality Index). The cognitive testing should take approximately 30-40 minutes. At the first session (pre-operation) only, dietary information will also be collected via a food frequency questionnaire, as well as measures of fluid and crystallised intelligence (the National Adult Reading Test and Block Design from the Wechsler Adult Intelligence Scale - Revised respectively). In addition, at each visit, a blood sample (maximum volume of 9mL, less than one tablespoon) will be taken from the participants for analysis of zinc concentration and markers of POCD and inflammation.

Recruitment information / eligibility
Status Withdrawn
Enrollment 0
Est. completion date June 23, 2021
Est. primary completion date June 23, 2021
Accepts healthy volunteers
Gender All
Age group 60 Years to 100 Years
Eligibility Inclusion Criteria: - Aged 60 years or over - Able to provide fully informed consent - Scheduled to undergo orthopaedic (knee/hip replacement) or colorectal surgery - English as their primary language Exclusion Criteria: - Under 60 years of age - Unable to provide fully informed consent - English not their primary language - Not electing to undergo any surgery or surgery that is not a knee or hip replacement, or colorectal surgery

Study Design

Related Conditions & MeSH terms

Intervention

Procedure:
• Elective surgery
Patients will be scheduled to undergo elective orthopaedic (knee/hip replacement) or colorectal surgery.

Locations
Country Name City State
United Kingdom Royal Berkshire Hospital Reading Berkshrie
United Kingdom School of Psychology and Clinical Languages, University of Reading Reading Berkshire

Sponsors (2)
Lead Sponsor Collaborator
University of Reading Royal Berkshire NHS Foundation Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome
Type Measure Description Time frame Safety issue
Primary Baseline zinc status as a predictor of POCD incidence 1-3 days post-operation Concentration of zinc in plasma/serum at baseline as a predictor for development of POCD 1-3 days post operation 1-3 days post operation
Primary Baseline zinc status as a predictor of POCD incidence at follow-up Concentration of zinc in plasma/serum at baseline as a predictor for development of POCD at follow-up One month post operation
Primary POCD risk biomarker as a predictor of POCD incidence 1-3 days post operation Concentration of POCD risk biomarker AZGP1 in plasma/serum at baseline as a predictor for development of POCD 1-3 days post operation 1-3 days post operation
Primary POCD risk biomarker as a predictor of POCD incidence at follow-up Concentration of POCD risk biomarker AZGP1 in plasma/serum at baseline as a predictor for development of POCD at follow-up One month post operation
Primary Baseline cognitive function (global Z score) as a predictor of POCD incidence 1- 3 days post operation Baseline cognitive function (global Z score) as a predictor for development of POCD 1-3 days post operation 1-3 days post operation
Primary Baseline cognitive function (global Z score) as a predictor of POCD incidence at follow-up Baseline cognitive function (global Z score) as a predictor for development of POCD at follow-up One month post operation
Secondary Baseline zinc status as a predictor of cognitive function (global Z score) 1-3 days Concentration of zinc in plasma/serum at baseline as a predictor of cognitive function (global Z score) 1-3 days post operation 1-3 days post operation
Secondary Baseline zinc status as a predictor of cognitive function (global Z score) at follow-up Concentration of zinc in plasma/serum at baseline as a predictor of cognitive function at follow-up One month post operation
Secondary Current zinc status and incidence of POCD 1-3 days post operation Correlation between concentration of zinc in serum/plasma 1-3 days post 1-3 days post operation
Secondary Current zinc status and incidence of POCD at follow-up Correlation between concentration of zinc in serum/plasma at follow-up and POCD incidence at follow-up One month post operation
Secondary Current zinc status and cognitive function (global Z score) 1-3 days post operation Correlation between concentration of zinc in serum/plasma 1-3 days post operation and cognitive function (global Z score) 1-3 days post-operation 1-3 days post operation
Secondary Current zinc status and cognitive function (global Z score) at follow-up Correlation between concentration of zinc in serum/plasma at follow-up and cognitive function (global Z score) at follow-up One month post operation
Secondary POCD risk biomarker AZGP1 at baseline as predictor of cognitive function (global Z score) 1-3 days post operation Concentration of AZGP1 in plasma/serum at baseline as a predictor of cognitive function (global Z score) 1-3 days post operation 1-3 days post operation
Secondary POCD risk biomarker AZGP1 at baseline as predictor of cognitive function (global Z score) at follow-up Concentration of AZGP1 in plasma/serum at baseline as a predictor of cognitive function (global Z score) at follow-up One month post operation
Secondary Correlation between POCD biomarkers (IL-6 and IL-2) 1-3 days post operation and POCD incidence 1-3 days post operation Correlation between the concentration of POCD biomarkers (IL-6 and IL-2) in plasma/serum 1-3 days post-operation and development of POCD 1-3 days post operation 1-3 days post operation
Secondary Correlation between POCD biomarkers (IL-6 and IL-2) at follow-up and POCD incidence at follow-up Correlation between the concentration of POCD biomarkers (IL-6 and IL-2) in plasma/serum at follow-up and development of POCD at follow-up One month post operation
Secondary Correlation between POCD biomarkers (IL-6 and IL-2) 1-3 days post operation and cognitive function (global Z score) 1-3 days post operation Correlation between the concentration of POCD biomarkers (IL-6 and IL-2) in plasma/serum 1-3 days post-operation and cognitive function (global Z score) 1-3 days post operation 1-3 days post operation
Secondary Correlation between POCD biomarkers (IL-6 and IL-2) at follow-up and cognitive function (global Z score) at follow-up Correlation between the concentration of POCD biomarkers (IL-6 and IL-2) in plasma/serum at follow-up and cognitive function (global Z score) at follow-up One month post operation
Secondary Mediating influence of POCD risk biomarker AZGP1 at baseline on a correlation between baseline zinc status and POCD incidence 1-3 days post operation Baseline concentration of POCD risk biomarker AZGP1 in serum/plasma as a mediator of a correlation between concentration of zinc in plasma/serum at baseline and POCD incidence 1-3 days post operation 1-3 days post operation
Secondary Mediating influence of POCD risk biomarker AZGP1 at baseline on a correlation between baseline zinc status and POCD incidence at follow-up Baseline concentration of POCD risk biomarker AZGP1 in serum/plasma as a mediator of a correlation between concentration of zinc in plasma/serum at baseline and POCD incidence at follow-up One month post operation
Secondary Mediating influence of POCD risk biomarker AZGP1 at baseline on a correlation between baseline zinc status and cognitive function (global Z score) 1-3 days post operation Baseline concentration of POCD risk biomarker AZGP1 in serum/plasma as a mediator of a correlation between concentration of zinc in plasma/serum at baseline and cognitive function (global Z score) 1-3 days post operation 1-3 days post operation
Secondary Mediating influence of POCD risk biomarker AZGP1 at baseline on a correlation between baseline zinc status and cognitive function (global Z score) at follow-up Baseline concentration of POCD risk biomarker AZGP1 in serum/plasma as a mediator of a correlation between concentration of zinc in plasma/serum at baseline and cognitive function (global Z score) at follow-up One month post operation
Secondary Mediating influence of POCD biomarkers (IL-6 and IL-2) on a correlation between zinc status and cognitive function (global Z score) 1-3 days post operation Concentration of POCD biomarkers (IL-6 and IL-2) in serum/plasma 1-3 days post operation as a mediator of a correlation between concentration of zinc in plasma/serum and cognitive function (global Z score) 1-3 days post operation 1-3 days post operation
Secondary Mediating influence of POCD biomarkers (IL-6 and IL-2) on a correlation between zinc status and cognitive function (global Z score) at follow-up Concentration of POCD biomarkers (IL-6 and IL-2) in serum/plasma at follow-up as a mediator of a correlation between concentration of zinc in plasma/serum and cognitive function (global Z score) at follow-up One month post operation
Secondary Mediating influence of baseline mood (PANAS) on a correlation between baseline cognitive function (global Z score) and POCD incidence 1-3 days post operation Baseline mood (PANAS) as a mediator of a correlation between baseline cognitive function (global Z score) and POCD incidence 1-3 days post operation 1-3 days post operation
Secondary Mediating influence of mood (PANAS) 1-3 days post operation on a correlation between baseline zinc status and cognitive function (global Z score) 1-3 days post operation Mood 1-3 days post operation (PANAS) as a mediator of a correlation between serum/plasma concentration of zinc at baseline and cognitive function (global Z score) 1-3 days post operation 1-3 days post operation
Secondary Mediating influence of mood (PANAS) at follow-up on a correlation between baseline zinc status and cognitive function (global Z score) at follow-up Mood (PANAS) at follow-up as a mediator of a correlation between concentration of zinc in plasma/serum at baseline and cognitive function (global Z score) at follow-up One month post operation
Secondary Mediating influence of mood (PANAS) at follow up on a correlation between zinc status and cognitive function (global Z score) at follow-up Mood (PANAS) at follow up as a mediator of a correlation between concentration of zinc in plasma/serum and cognitive function (global Z score) at follow-up One month post operation
See also
  Status Clinical Trial Phase
Recruiting NCT05273125 - MOBility Disorders Assessment in Patients With Mild COGnitive Disorders
Active, not recruiting NCT04049695 - Improving Cognition After Cancer N/A
Completed NCT05912374 - Adapting a Behavioral Intervention to Accommodate Cognitive Dysfunction in People Who Inject Drugs N/A
Recruiting NCT03977350 - Association Between qEEG Measure and Post-Operative Cognitive Dysfunction (POCD) and Postoperative Delirium (POD)
Not yet recruiting NCT06027632 - Remotely Supervised Computerized Cognitive Stimulation to Reduce Post-chemotherapy Cognitive Difficulties in Patients Treated for Localized Breast Cancer N/A
Terminated NCT00754013 - Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10 Phase 3
Completed NCT00719628 - Depth of Anaesthesia and Cognitive Dysfunction N/A
Terminated NCT00754052 - Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 11 To 17 Phase 3
Recruiting NCT05014399 - Cognitive Impairment in Colorectal Cancer Patients Receiving Cytotoxic Chemotherapy
Completed NCT04966455 - Effect of Raisins on Cognitive Function in Healthy Older Adults Phase 3
Recruiting NCT05372159 - Vanderbilt Memory and Aging Project
Completed NCT03243279 - BRS and Outcomes in Cardiothoracic Surgery
Completed NCT04093882 - The Relevance of the Blood-brain Barrier to Cognitive Dysfunction and Alzheimer's Disease
Recruiting NCT05732285 - A Pilot Randomized Controlled Trial: CoINTEGRATE N/A
Completed NCT06059768 - Urdu Translation and Psychometric Analysis of Lawton IADLS.
Completed NCT04562662 - Evaluation of mediVR-KAGURA Guided Therapy N/A
Completed NCT04624529 - Validity and Reliability of a Self-evaluation Tool for Cognitive Deficits in the Acute Stage After Stroke
Not yet recruiting NCT04079075 - Multiple Interventions to Prevent Cognitive Decline N/A
Active, not recruiting NCT04638101 - Building the Path to Resilience in Preterm Infants: Mindfulness-based Intervention N/A
Active, not recruiting NCT04556305 - Lifestyle Physical Activity and Cognitive Training Interventions N/A